Emmanouil Pagkalos

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Heart rate variability modifications following exercise training in type 2 diabetic patients with definite cardiac autonomic neuropathy

M Pagkalos, Evangelia Kouidi, Emmanouil Pagkalos et al. · British Journal of Sports Medicine · 2007 · 104 citations

Effectiveness and tolerability of second‐line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real‐life worldwide observational study (<scp>EDGE</scp>)

Chantal Mathieu, Anthony Barnett, Helmut Brath et al. · International Journal of Clinical Practice · 2013 · 55 citations · Full text

The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension

Pantelis Sarafidis, Anastasios N. Lasaridis, P NILSSON et al. · American Journal of Hypertension · 2005 · 48 citations